BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31128056)

  • 1. The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-κb), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients.
    Prajoko YW; Aryandono T
    Asian Pac J Cancer Prev; 2019 May; 20(5):1511-1518. PubMed ID: 31128056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
    Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
    Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
    Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
    Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer.
    Sakakibara M; Fujimori T; Miyoshi T; Nagashima T; Fujimoto H; Suzuki HT; Ohki Y; Fushimi K; Yokomizo J; Nakatani Y; Miyazaki M
    Cancer; 2012 Aug; 118(16):3899-910. PubMed ID: 22180194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
    Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
    Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
    Minato T; Yamamoto Y; Seike J; Yoshida T; Yamai H; Takechi H; Yuasa Y; Furukita Y; Goto M; Bando Y; Tangoku A
    Ann Surg Oncol; 2013 Jan; 20(1):209-17. PubMed ID: 22847125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.
    Prajoko YW; Aryandono T
    Asian Pac J Cancer Prev; 2014; 15(2):595-8. PubMed ID: 24568463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy.
    Deng Y; Zhou J; Fang L; Cai Y; Ke J; Xie X; Huang Y; Huang M; Wang J
    Br J Cancer; 2014 Jan; 110(2):430-4. PubMed ID: 24327017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldehyde dehydrogenase 1 as a predictor of the neoadjuvant chemotherapy response in breast cancer: A meta-analysis.
    Li J; Zhang B; Yang YF; Jin J; Liu YH
    Medicine (Baltimore); 2018 Aug; 97(34):e12056. PubMed ID: 30142860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of NF-kB as a predictor of neoadjuvant chemotherapy response in breast cancer.
    Sampepajung E; Hamdani W; Sampepajung D; Prihantono P
    Breast Dis; 2021; 40(S1):S45-S53. PubMed ID: 34057118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
    Ito M; Shien T; Omori M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
    Breast Cancer; 2016 May; 23(3):437-44. PubMed ID: 25599843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
    Kida K; Ishikawa T; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Breast Cancer Res Treat; 2016 Apr; 156(2):261-9. PubMed ID: 26975188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy.
    Khoury T; Ademuyiwa FO; Chandrasekhar R; Jabbour M; Deleo A; Ferrone S; Wang Y; Wang X
    Mod Pathol; 2012 Mar; 25(3):388-97. PubMed ID: 22080062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins].
    Yang TY; Yi W; Wen J; Gan CY; Yang YC; Dai M
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):118-123. PubMed ID: 30862141
    [No Abstract]   [Full Text] [Related]  

  • 19. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer.
    Lee A; Won KY; Lim SJ; Cho SY; Han SA; Park S; Song JY
    Pathol Res Pract; 2018 May; 214(5):619-624. PubMed ID: 29685462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.